抗凝药物在血流动力学稳定的肺栓塞患者治疗中的研究进展  

Research Progress of Anticoagulant Drugs in the Treatment of Hemodynamically Stable Pulmonary Embolism Patients

作　　者：孟媛 党乐婷 温红侠[2] 

机构地区：[1]西安医学院,陕西 西安 [2]陕西省人民医院呼吸内科,陕西 西安

出　　处：《临床医学进展》2023年第4期5872-5878,共7页Advances in Clinical Medicine

摘　　要：由于近年来新型口服抗凝药物的出现,肺栓塞患者的药物治疗不再是单一的通过静脉注射肝素和/或维生素k拮抗剂进行抗凝治疗。新型抗凝药物的出现给肺栓塞患者提供更多、更优的治疗方案。在特殊人群,如合并肥胖、肝衰竭、肾衰竭、高龄、恶性肿瘤、儿童和新型冠状病毒感染等,可以根据不同人群选择不同的抗凝药物,制定个体化的抗凝方案。Due to the emergence of new oral anticoagulants in recent years, medical treatment for patients with pulmonary embolism is no longer a single anticoagulant therapy with intravenous heparin and/or vitamin k antagonists. The emergence of new anticoagulant drugs provides more and better treatment options for patients with pulmonary embolism. Especially in special populations, such as obesity, liver failure, kidney failure, the elderly, malignant tumors, children and novel coronavirus infection, different anticoagulant drugs can be selected according to different populations, and indi-vidualized anticoagulant programs can be developed.

关 键 词：肺栓塞 抗凝剂 直接口服抗凝剂 

分 类 号：R56[医药卫生—呼吸系统]